ZIM Laboratories (ZIMLAB) Fundamentals 2026 — P/E 97.9x, Revenue Analysis | SniperIQ
ZIM Laboratories (ZIMLAB) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹624 Crore, trading at ₹116.52 on the NSE. This SniperIQ fundamentals page covers ZIM Laboratories's valuation (P/E 97.9x, P/B 1.9x), profitability (net margin 1.6%), revenue (₹369 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is ZIM Laboratories's market cap?
ZIM Laboratories (ZIMLAB) has a market capitalization of approximately ₹624 Crore, trading at ₹116.52 on the NSE. Market cap moves with the live share price.
What is ZIM Laboratories's P/E ratio?
ZIM Laboratories's trailing twelve-month P/E ratio is 97.9x, with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is ZIM Laboratories?
ZIM Laboratories runs a net profit margin of 1.6%, a gross margin of 38.6%, and an operating margin of 2.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ZIM Laboratories generate?
ZIM Laboratories reported revenue of ₹369 Crore for fiscal year 2026, with net income of ₹6 Crore and earnings per share (EPS) of 1.19. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does ZIM Laboratories pay a dividend?
ZIM Laboratories does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is ZIM Laboratories financially healthy?
ZIM Laboratories carries a debt-to-equity ratio of 0.43x and a current ratio of 1.45x, with a market beta of 0.83. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ZIM Laboratories a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ZIM Laboratories (ZIMLAB) the key facts are: market cap ₹624 Crore, P/E 97.9x, revenue ₹369 Crore, 52-week range 59.31-133.9. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track ZIM Laboratories's full fundamentals live
Get ZIM Laboratories's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.